CS-8958 Clinical Pharmacology study - Safety and pharmacokinetics of nebulized laninamivir octanoate (CS-8958) after a single inhaled administration in healthy male Japanese subjects -
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Laninamivir (Primary)
- Indications Influenza virus infections
- Focus Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 23 Oct 2017 Results published in the Antimicrobial Agents and Chemotherapy
- 27 Jun 2017 Results evaluating the the safety and pharmacokinetics of nebulized laninamivir octanoate and laninamivir in healthy male Japanese subjects, presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics.
- 17 Jun 2016 Status changed from not yet recruiting to completed.